1. Home
  2. TRIN vs EVO Comparison

TRIN vs EVO Comparison

Compare TRIN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trinity Capital Inc.

TRIN

Trinity Capital Inc.

HOLD

Current Price

$15.07

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.27

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIN
EVO
Founded
2007
1993
Country
United States
Germany
Employees
N/A
4766
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TRIN
EVO
Price
$15.07
$3.27
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$16.00
$7.00
AVG Volume (30 Days)
1.4M
132.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
13.50%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.26
N/A
Revenue Next Year
$6.94
$7.13
P/E Ratio
$7.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.97
$2.84
52 Week High
$17.20
$4.80

Technical Indicators

Market Signals
Indicator
TRIN
EVO
Relative Strength Index (RSI) 43.02 43.64
Support Level $14.39 $2.87
Resistance Level $15.23 $3.78
Average True Range (ATR) 0.43 0.10
MACD -0.05 -0.04
Stochastic Oscillator 43.64 43.57

Price Performance

Historical Comparison
TRIN
EVO

About TRIN Trinity Capital Inc.

Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: